Why Is CELLDEX THERAPEUTICS (CLDX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 23, 2026 at 12:04 AM ET · reviewed against 16 wire stories
CELLDEX THERAPEUTICS (CLDX) is down -11.56% in the latest session. Our newswire has captured 16 stories on CLDX across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Celldex Therapeutics (CLDX) fell 11.56% to $33.51 in a single session, marking a sharp reversal for the biopharmaceutical company. The decline followed the release of positive Phase 3 trial results for barzolvolimab in chronic spontaneous urticaria, which were accompanied by growing concerns over safety data. While the drug met its primary and secondary endpoints, investor sentiment turned negative as reports highlighted potential safety issues that could delay regulatory approval.
What Happened
Celldex Therapeutics announced positive topline data from the EMBARQ-CSU1 and EMBARQ-CSU2 trials, showing barzolvolimab achieved a complete response rate of nearly 54% at 24 weeks in antihistamine-refractory chronic spontaneous urticaria patients. The company presented the results in a slide deck on September 22, 2026. However, media reports and analyst commentary quickly shifted focus to safety concerns, with Reuters noting that these issues overshadowed the clinical success. H.C. Wainwright called the safety concerns “misplaced” and reiterated a positive view, while Stifel and other analysts maintained Buy ratings. Despite this, the market reacted negatively, sending the stock sharply lower.
What The Data Shows
The stock has declined 8.1% over the last eight sessions, moving from $36.90 to $33.92. On September 22, it printed 22 fresh 52-week lows and only four 52-week highs, reflecting heightened volatility. The 52-week range remains $22.10 to $45.14. Celldex operates with a market cap of $3.0 billion but remains unprofitable, with a TTM EPS of -4.33 and TTM revenue down 97.3%. H.C. Wainwright raised its price target to $64 from $42, and both Morgan Stanley and Barclays increased their targets to $46 and $53, respectively.
What To Watch
Celldex is preparing for a 2027 FDA submission for barzolvolimab in chronic skin disease. Investors should monitor how regulatory agencies assess the safety data and whether the company can address concerns ahead of its filing.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AI sentiment, last 36h · averaged over 16 stories · 57/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
13h agoSeeking AlphaBULLISH 73Product/PR
Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow
2026-09-22. The following slide deck was published by Celldex Therapeutics, Inc.
15h agoInvesting.com MarketsBEARISH 34General
Why is Celldex Therapeutics stock sliding today?
Why is Celldex Therapeutics stock sliding today?
15h agoStocktwits NewsNEUTRAL 54Analyst
CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’
H.C. Wainwright called the Phase 3 results a “compelling” late-stage assessment of Barzolvolimab in a patient population with a significant unmet need.
16h agoThe FlyBEARISH 34General
Celldex falls -11.4%
16h agoThe FlyBULLISH 67Analyst
Celldex price target raised to $64 from $42 at H.C. Wainwright
17h agoMarketChameleonBULLISH 76Product/PR
Celldex Highlights Phase 3 Barzolvolimab Data With Complete Response Near 54% at 24 Weeks in CSU
September 22, 2026
Celldex reported positive topline Phase 3 results from EMBARQ-CSU1 and EMBARQ-CSU2, with barzolvolimab meeting the primary endpoint and all key secondary endpoints in antihistamine-refractory chronic spontaneous urticaria. Complete response (UAS7=0) reached as high as 54.0% at 24 weeks, with statistically significant benefits also shown in omalizumab-refractory patients and in angioedema resolution. The program continues to 52 weeks, and Celldex said a BLA submission is anticipated in 2027.
Stifel reiterates Celldex Therapeutics stock Buy rating after trial data
Stifel reiterates Celldex Therapeutics stock Buy rating after trial data
17h agoReutersBEARISH 38General
Celldex shares slip as safety concerns cloud skin drug trial win
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →